Clinically, high expression levels of the components of the Galectin-3-β-catenin-IGFBP3/vimentin axis were closely correlated with vascular metastasis-driven sorafenib resistance and poor survival in large-scale HCC samples. This evidence concerns the gene LGALS3 and hepatocellular carcinoma.